Dysgerminoma

Published on 10/03/2015 by admin

Filed under Obstetrics & Gynecology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1524 times

Dysgerminoma

Synonyms/Description

Malignant germ cell tumor diagnosed predominantly in young adults ages 20 to 30. The most common benign germ cell tumor is the mature teratoma, commonly called a dermoid cyst (see Dermoid Cyst).

Etiology

Primitive germ cell tumors include the dysgerminoma, immature teratoma, endodermal sinus/yolk sac tumor, embryonal carcinoma, and nongestational choriocarcinoma.
Ovarian dysgerminomas arise from primordial germ cells and represent 1% to 2% of ovarian malignancies and 30% of all malignant germ cell tumors. Dysgerminoma is a rare tumor similar in histology to the male testicular seminoma and can arise bilaterally in 15% of affected patients. Serum human chorionic gonadotropin (hCG) is occasionally elevated.

Ultrasound Findings

Findings involve a solid, mostly isoechoic, but heterogeneous mass with apparent lobulations. The lobulations are caused by inhomogeneous internal echogenicity giving the sonographic appearance of different compartments in this solid tumor. Blood flow is moderate to abundant in most lesions, indicating a high risk of malignancy.

Differential Diagnosis

The solid appearance of this tumor makes the differential diagnosis extensive. Struma ovarii (ectopic thyroid tissue, monodermal teratoma) can have a similar appearance although less vascular. Other solid ovarian malignancies should be considered, including metastatic disease to the ovary, lymphoma, and predominantly solid cystadenocarcinomas (although the common cystic portions of these cystadenocarcinomas are not usually seen in dysgerminomas). The extensive blood flow makes the fibroma and mature dermoid unlikely.

Clinical Aspects and Recommendations

Dysgerminomas may present either as palpable adnexal masses or as incidental findings on an imaging study. Occasionally, these tumors display unusually rapid growth, and patients may present with abdominal enlargement and pain caused by rupture with hemoperitoneum or torsion. If the tumor is hormonally active, menstrual abnormalities may occur. These tumors can produce placental alkaline phosphatase and LDH. Thus, in patients with a solid-appearing adnexal mass, assessment of such tumor markers may be helpful. An occasional patient may produce hCG but virtually never produces alpha fetoprotein (AFP). Studies indicate that approximately 75% of women with dysgerminomas present with stage I disease. There is bilateral involvement in approximately 10% to 15% of cases. Because the ultrasound findings are nonspecific, treatment is surgical exploration and resection in virtually all cases. These patients are often young and have not completed their child bearing; therefore, unilateral salpingo-oophorectomy is appropriate and is curative in most cases.

Figure

image

Figure D2-1 Dysgerminoma (two patients). A and B, Solid rounded lobular ovarian mass with no visible cystic component. C, Color flow Doppler of the mass shows blood flow pattern in a different patient with dysgerminoma.

Suggested Reading

Gordon A., Lipton D., Woodruff J.D. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol. 1981;58:497–504.

Guerriero S., Testa A.C., Timmerman D., Van Holsbeke C., Ajossa S., Fischerova D., Franchi D., Leone F.P., Domali E., Alcazar J.L., Parodo G., Mascilini F., Virgilio B., Demidov V.N., Lipatenkova J., Valentin L. Imaging of gynecological disease (6): clinical and ultrasound characteristics of ovarian dysgerminoma. Ultrasound Obstet Gynecol. 2011;37:596–602.

Kim S.H., Kang S.B. Ovarian dysgerminoma: color Doppler ultrasonographic findings and comparison with CT and MR imaging findings. J Ultrasound Med. 1995;14:843–848.

Vicus D., Beiner M.E., Klachook S., Le L.W., Laframboise S., Mackay H. Pure dysgerminoma of the ovary 35 years on: a single institutional experience. Gynecol Oncol. 2010;117:23–26.